Rebound bei Affymetrix !
Seite 2 von 4 Neuester Beitrag: 24.04.21 23:37 | ||||
Eröffnet am: | 30.11.08 05:33 | von: Chalifmann3 | Anzahl Beiträge: | 79 |
Neuester Beitrag: | 24.04.21 23:37 | von: Simoneqjtoa | Leser gesamt: | 22.338 |
Forum: | Hot-Stocks | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 > |
Monday December 8, 8:00 am ET
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX - News) today announced the completion of its acquisition of Panomics, Inc., a privately held, Fremont, Calif.-based company which offers a powerful suite of assay products for a wide variety of low- to mid-plex genetic, protein, and cellular analysis applications.
“The acquisition of Panomics will strengthen our position in the high-growth market segments of validation and routine testing and create further operating leverage,” said Kevin King, president of Affymetrix. “Customers will benefit from a more complete workflow, beginning with whole-genome Affymetrix microarray studies and then using Panomics products to focus on genes and proteins of interest.”
Panomics has grown rapidly with a number of easy-to-use, low- to mid-plex products and sells into an installed base of more than 5,600 instruments worldwide. These products cover a broad range of sample types and offer a direct assay approach with high sensitivity and specificity.
The assays do not require nucleic acid extraction or amplification, which streamlines workflows for applications such as gene expression, copy number, and cytogenetics. Panomics products complement Affymetrix’ recently acquired liquid array technology and will enable the company to address low- to mid-plex genetic analysis requirements more effectively.
In connection with the completion of the acquisition, Affymetrix is paying approximately $73 million in cash to acquire Panomics.
Affymetrix will host a conference call on January 29, 2009 at 2 p.m. PT to review its operating results for the fourth quarter and fiscal year 2008. The company will also discuss the impact of the acquisition on this call. A live webcast can be accessed by visiting the Investor Relation section of the Company’s website at www.affymetrix.com. In addition, investors and other interested parties can listen by dialing domestic: (866) 500-AFFX, international: (706) 643-2771.
About Panomics
Panomics is a privately held life science company which offers a platform of reagents and products that enable the multiplex measurement of molecular events, such as intracellular pathway analysis, cell signaling, and gene expression profiling, in a quantitative and scalable manner. Panomics has grown rapidly on the value of its proprietary branched DNA technology for gene expression analysis in cell-based assays, as well as its signal transduction and transcription factor assays. Formerly named Genospectra, Panomics was founded in 2000 and is based in Fremont, Calif. For more information, please visit www.panomics.com.
Und vola,bist du mittlerweile drin ?
MFG
Chali
das überzeugt, jetzt geh ich mal rein.
Tuesday December 9, 8:00 am ET
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX - News) today announced that its technology was used by the Cincinnati Children?s Hospital Medical Center to develop an innovative molecular diagnostic test designed to help diagnose the genetic defects in patients with inheritable forms of jaundice. Jaundice is the most common symptom of liver disease in young children. Cincinnati Children?s has made the CLIA- and CAP-approved laboratory developed test available to clinicians around the world.
Research shows jaundice occurs in one out of every 2,200 live births in the U.S.1 Although many cases resolve spontaneously, patients with pathologic jaundice (also known as cholestasis) may progress to end-stage liver disease or cirrhosis. Until now, evaluation has frequently determined the extent of liver injury in patients with jaundice. Cincinnati Children?s intends the Jaundice Chip to enable diagnoses to be expanded to include genetic causes and more precisely identify patients at high risk for progressive liver disease.
A team of scientists led by Jorge Bezerra, M.D., professor of pediatrics and director of gastroenterology research at Cincinnati Children?s, designed the Jaundice Chip, a custom microarray. In a study published in the January 2007 issue of the Journal of Gastroenterology, Dr Bezerra reported the Jaundice Chip is highly effective in detecting the five most common genetic mutations in children with inherited causes of jaundice. Those five diseases represent about half of all pediatric chronic liver disease cases.2
?We are proud of the team at Cincinnati Children?s for creating a custom array that enables researchers to draw clearer conclusions as to the causes of jaundice,? said Kevin King, president of Affymetrix. ?This test is further proof of Affymetrix enabling scientists to innovate and use our products to meet the unmet needs of the market.?
Affymetrix offers a continuous path to discover, develop, and commercialize complex biomarker signature assays. The GeneChip? System 3000Dx is the only microarray instrumentation platform to receive regulatory clearance by the U.S. FDA and to be CE marked in the European Union for in vitro diagnostic use. The CLIA-certified Affymetrix Clinical Services Laboratory (ACSL) offers microarray-based molecular diagnostic patient and clinical trial testing services which enable customers to leverage Affymetrix' technology and experience to bring more effective molecular diagnostic tests to patients faster than ever before.
1 Arya G. et al., Pediatric liver disease in the United States: epidemiology and impact, J. Gastroenterol. Hepatol, 17(5): 521-5, (May 2002)
2 Liu C. et al., Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis, J. Gastroenterol. Hepatol, 132(1):119-26. (Jan 2007)
For more information on the Jaundice Chip developed on the Affymetrix platform, visit Cincinnati Children?s at: http://www.cincinnatichildrens.org/health/.../05-07/jaundice-chip.htm
MFG
Chali
MFG
Chali
MFG
Chali
geil! und ich bin dabei, auch wenn ichs nur hingelegt habe.
die Zahlen und ausblick waren schlecht,ich würde den gewinn jetzt mitnehmen und verkaufen,oder hast du schon ?
MFG
Chali
Technologie,der Kurs ,das Volumen,die Performance !! Hier passt einfach alles,würde mich freuen ,wenn du den Thread hier am Leben erhieltest und vielleicht sogar in affymetrix einsteigst,denn mehr als "Sequenom" haben die allemal drauf .....
MFG
Chali
Was denkt ihr?
Umsatzrückgang von ca. 12 % steht ein Kursrückgang von über 40% gegenüber
Meiner Meinung nachvollkommen ungerechtfertigt!
Diese Aktie kommt erstmal ganz weit hoch auf meine Watchlist,und sollte es weiter abwärtsgehen, werd ich mir mal ein paar aktien ins depot legen ;)
Nur meine Meinung^^ meld mich spätestens in 2 Monaten wieder, mal sehen wo sie dann steht
MFG
Chali